Browsing tag:

prostate cancer


Known as the prostate cancer powerhouse treatment Zytiga, Abiraterone Acetate has recently become a sales powerhouse for Medivation. The reason for the hype centers on a new indication for this potent anti-cancer drug, specifically as an efficacious pre-chemo treatment. Initial FDA approval for Abiraterone was for post-chemotherapy only. As a post-chemo treatment Zytiga was by[…]

Read More

Patients with late-stage prostate cancer stand to benefit greatly since the approval of Enzalutamide, CAS number 915087-33-1. Sales of the brand name of Enzalutamide, Xtandi, have recently proven to garnish sizable profits for Medivation, the biopharmaceutical parent of this wonder drug. The launch of Enzalutamide in Europe and Asia in upcoming months are projected to[…]

Read More

Cabazitaxel was approved by the FDA in 2010 as the brand name Jetvana, for the treatment of advanced prostate cancer. Cabazitaxel, CAS number 183133-96-2, is an anti-cancer medication that is typically prescribed alongside the steroid prednisone. Patients that have become resistant to docetaxel or other cancer treatments may find success with cabazitaxel. Adverse effects are[…]

Read More

Used to treat the symptoms of prostate cancer, Triptorelin Acetate CAS# 149194-24-7 is a man-made form of a hormone that regulates many functions in the body. Triptorelin is effectual at over stimulating the body’s own production of these specific hormones, therefore causing the production of these hormones to shut down. This shut down is triggered[…]

Read More

Itraconazole is an azole antifungal medicine. Known as the brand name Sporanox, which is marketed Janssen, the patent for this potent product expires on January 13, 2015. Itraconazole works by interfering with the formation of the fungal cell membrane. It is a formidable product for treating infections caused by fungus, which can invade any part[…]

Read More

Denosumab, CAS number 615258-40-7, offers divergent options for researchers working with this monoclonal antibody. The scope of efficacy for denosumab is wide, with one of it’s uses being an approved treatment of osteoporosis in women, particularly those women who are post menopausal. Known as the brand Prolia®, which is marketed by Amgen, denosumab is effectively[…]

Read More

Although not brand new, Toremifene has been found to be as effective as Tamoxifen, in breast cancer, as a selective estrogen receptor modulator (SERM) with the added advantage of better patient tolerability and lesser adverse effects. Several drugs for this specific type of cancer have been developed but only a handful has made it to[…]

Read More

On Wednesday January 26, 2011, GlaxoSmithKline (GSK) announced that the Company has received a Complete Response letter from the U.S. Food and Drug Administration (FDA) for the supplemental New Drug Application (sNDA) for Avodart® (Dutasteride CAS# 164656-23-9 available for R&D purposes from LGM Pharma, a US based API supplier) for reducing the risk of prostate[…]

Read More